Recent Updates
Recently added Catalysts
UTHR Positive Sentiment

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

Monday, August 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: United Therapeutics Corporation announced that the FDA has accepted its New Drug Application for ralinepag, aimed at treating pulmonary arterial hypertension (PAH). The FDA has set a target action date of June 24, 2027, for the review. Currently, ralinepag remains investigational and has not been approved for any indication.

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA accepted the NDA for ralinepag.
  • Potential to significantly impact treatment for PAH.
  • Target action date set for June 24, 2027.

CONCERNS & RISKS

  • Ralinepag is still investigational and not yet approved.
  • No prior FDA approvals for any indication.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+21%
120-day peak, hindsight
Typical move
10.8%
average across 6 past catalysts
Lead asset
UBT251
Phase 2 · Obesity &Amp; Overweight

Full Press Release Details

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. “Ralinepag has the potential to make an important difference

Frequently Asked Questions

What is ralinepag used for?

Ralinepag is being developed to treat pulmonary arterial hypertension (PAH).

When is the FDA's target action date for ralinepag?

The FDA's target action date for ralinepag is June 24, 2027.

Has ralinepag been approved by the FDA?

No, ralinepag has not been approved for any indication by the FDA.

What company is developing ralinepag?

Ralinepag is being developed by United Therapeutics Corporation.

ShareAdd on Google
Tags: UTHR Viatris Investor Conferences Healthcare United Therapeutics ralinepag FDA pulmonary arterial hypertension NDA
Last updated: Aug 24, 2026

Biotech snapshot

Cash runway
$3803M liquidity · $0M/mo burn
Low dilution risk
Lead asset
UBT251Phase 2
Obesity &Amp; Overweight →

Catalyst track record

+21%
best trade around UTHR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for UTHR.

See every catalyst's timing & PoA →